Biologics have been shown to constitute a highly effective treatment for patients with
psoriasis. However, a significant number of patients treated with biologics will discontinue …

Background The evidence for adding small-molecule drugs to an ongoing biologic treatment
is sparse, but combination therapies appear to be advantageous in appropriately selected …

Objectives To investigate the survival of apremilast in a cohort of psoriasis patients treated
with apremilast in a Greek hospital. Methods A retrospective cross-sectional study examined …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Apremilast is the first small molecule approved for the treatment of moderate to severe
psoriasis and psoriatic arthritis in adult patients. To evaluate survival, efficacy and safety of …

Objectives The aim of this paper is to present our personal as well as literature-sourced real-
world evidenced on apremilast use in psoriasis patients with serious baseline comorbidities …

There is limited evidence about the real‐world survival of apremilast in patients with
psoriasis, especially over the long term. To evaluate the long‐term survival of apremilast and …

Few real‐life studies evaluated long‐term apremilast therapy in the variable spectrum of
clinical‐anamnestic features which can be found in psoriatic arthritis (PsA) patients. This real …

Introduction: Biologics have transformed the management of moderate-to-severe psoriasis.
The risk of developing a malignancy during treatment is an important consideration, and …

Introduction Apremilast is a drug recently developed for psoriasis. Few data are available on
its use in the elderly. We evaluated the tolerance and effectiveness of apremilast used in …